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Abstract
Although invasive infections and mortality caused by Candida species are increasing among compromised patients, 
resistance to common antifungal agents is also an increasing problem. We analyzed 60 yeasts isolated from patients 
with invasive candidiasis using a PCR/RFLP strategy based on the internal transcribed spacer (ITS2) region to identify 
different Candida pathogenic species. PCR analysis was performed from genomic DNA with a primer pair of the 
ITS2‑5.8S rDNA region. PCR‑positive samples were characterized by RFLP. Restriction resulted in 23 isolates identified 
as C. albicans using AlwI, 24 isolates as C. parapsilosis using RsaI, and 13 as C. tropicalis using XmaI. Then, a group 
of all isolates were evaluated for their susceptibility to a panel of previously described killer yeasts, resulting in 75% 
being susceptible to at least one killer yeast while the remaining were not inhibited by any strain. C. albicans was the 
most susceptible group while C. tropicalis had the fewest inhibitions. No species‑specific pattern of inhibition was 
obtained with this panel of killer yeasts. Metschnikowia pulcherrima, Pichia kluyveri and Wickerhamomyces anomalus 
were the strains that inhibited the most isolates of Candida spp.
Keywords: Candida, killer yeasts, yeast antagonism.
Identificação e susceptibilidade de isolados clínicos de Candida spp. para 
toxinas assassinas
Resumo
Embora as infecções invasivas e a mortalidade causada por espécies de Candida estejam aumentando entre pacientes 
comprometidos, a resistência a agentes antifúngicos comuns também é um problema crescente. Analisamos 60 leveduras 
isoladas de pacientes com candidíase invasiva utilizando como estratégia PCR/RFLP baseada na região espaçadora 
transcrita interna (ITS2) para identificar diferentes espécies patogênicas de Candida. A análise por PCR foi realizada 
a partir de ADN genómico com um par de iniciadores da região ITS2‑5.8S rDNA. As amostras PCR‑positivas foram 
caracterizadas por RFLP. A restrição resultou em 23 isolados identificados como C. albicans usando AlwI, 24 isolados 
como C. parapsilosis usando RsaI e 13 como C. tropicalis usando XmaI. Em seguida, avaliou-se o grupo de todos 
os isolados quanto à sua susceptibilidade a um painel de leveduras killer previamente descritas, resultando em 75% 
sendo suscetíveis a pelo menos uma levedura killer, enquanto que as restantes não foram inibidas por qualquer cepa. 
C. albicans foi o grupo mais suscetível enquanto C. tropicalis teve o menor número de inibições. Não se obteve um 
padrão de inibição específico da espécie com este painel de leveduras killer. Metschnikowia pulcherrima, Pichia kluyveri 
e Wickerhamomyces anomalus foram as cepas que inibiram a maioria dos isolados de Candida spp.
Palavras-chave: Candida, levedura killer, antagonismo de leveduras.
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1. Introduction
Invasive infections caused by primary and opportunistic 
fungal pathogens have increased in immunocompromised 
patients for over two decades (Beck-Sagué and Jarvis, 
1993). Most of these life‑threatening infections are caused 
by different Candida species, which represent the most 
commonly yeasts isolated from bloodstream infections in 
patients in intensive care units and are the second cause 
of mortality in such patients (Wisplinghoff et al., 2004). 
In Mexico, the most frequent species is C. albicans 
(70%), but the proportion of infections caused by 
Non-albicans Candida species (30%) has been increasing 
(Hernández-Hernández et al., 2003).
Mortality associated to Candida infections ranges 
from 40% to 60% (Nucci et al., 1997). Furthermore, in 
the last decade, the emergence of infections caused by 
Candida species resistant to common antifungal agents 
has been increasing, such as those caused by C. krusei 
and C. glabrata resistant to fluconazole. Therefore, 
proper identification at species level is essential to provide 
appropriate therapy and reduce mortality in patients with 
invasive candidiasis. Furthermore, efforts are being made 
in order to develop new antifungal therapies that could 
overcome such resistances with a potential candidate being 
killer toxins secreted from other yeasts.
The killer phenomenon was described by Bevan 
and Makower (1963) and consists of the secretion of 
proteinaceous compounds (killer toxins) from yeasts 
that inhibit the growth of other yeasts. These killer toxins 
exhibit variations in their inhibition spectrum, mechanism 
of action, molecular size, optimum pH and temperature, 
and they have been described in more than 20 genera of 
yeast from both the ascomycetes and basidiomycetes phyla 
(Golubev, 1998), from either clinical or natural sources 
(Souza Cabral et al., 2009; Arroyo-Helguera et al., 2012). 
Reports from Magliani et al. (2004) and Polonelli et al. 
(2003) have shown that killer toxins pose an interesting 
strategy for the development of new antifungal treatments 
that could overcome antifungal resistance due to the 
evolutionary origin of these interactions.
In this study, we used a PCR/RFLP strategy based 
on the ITS2 region to identify at species level 60 clinical 
Candida isolates and then subjected them to a panel of 
previously isolated killer yeasts of diverse origin in order 
to evaluate their potential therapeutic application and 
look for patterns that may differentiate among species, 
as a potentially fast and low‑cost identification technique.
2. Material and Methods
2.1. Killer yeasts
A panel of 19 previously isolated killer yeasts was selected, 
isolated and identified by Dr. Marcela Sangorrín (Table 1). 
The killer yeasts were identified by ITS1‑5.8S‑ITS2 rDNA 
PCR-RFLP analysis as described by Esteve-Zarzoso et al. 
(1999). Patterns obtained for each isolate after digestion 
with the restriction enzymes Cfo I, Hae III and Hinf l 
were compared with those of reference strains available 
in the yeast identification database (Esteve-Zarzoso et al., 
1999). Yeast identity was confirmed by sequencing the 
D1/D2 domains of the 26S rRNA gene (Kurtzman and 
Robnett, 1998). The sequences obtained for yeast isolates 
were compared with those published at GenBank database 
(available at the National Center for Biotechnology 
Information, NCBI) using BLAST.
2.2. Clinical isolates
A total of 60 clinical isolates were obtained from 
the mycology laboratory of the Centro Regional para el 
Control de Enfermedades Infecciosas at the Universidad 
Autónoma de Nuevo León. All Candida strains were grown 
on YPD broth (1% yeast extract, 2% casein peptone and 
2% dextrose) for 24 hours at 37°C with shaking (230 rpm). 
Yeast identification was previously performed using the 
API 20 C AUX test (bioMérieux Vitek, Hazelwood, MO, 
USA) according to manufacturer’s instructions.
2.3. DNA isolation
Yeast DNA was obtained by the technique described 
by Sambrook and Russell (2001). For cell wall disruption 
and subsequent extraction of DNA, we used the method 
described by Jin et al. (2004), with modifications. In brief, 
cells of each fungal culture were homogenized in 500 µL 
of lyticase lysis buffer (50 mMtris, pH 7.6; 1 mM EDTA, 
0.2% 2‑mercaptoethanol, 10 μL of lyticase 5 U/μL) and 
incubated for 10 minutes at 37°C. Cell wall disruption 
was performed by mixing with glass beads in a vortex. 
Extraction of DNA was carried out by precipitation with 
phenol-chloroform and 70% ethanol. Finally, DNA was 
resuspended in 20 μL of TE buffer (10 mMTris‑HCl, 
Table 1. Killer yeasts evaluated for their inhibitory activity 
of clinical isolates of Candida spp.
Strain No. ID
1250 Pichia membranifaciens
1127 Metschnikowia pulcherrima
1144 Metschnikowia pulcherrima
1123 Metschnikowia pulcherrima
1023 Metschnikowia pulcherrima
1025 Wickerhamomyces anomalus
1027 Wickerhamomyces anomalus
1015 Wickerhamomyces anomalus
1018 Wickerhamomyces anomalus
1026 Wickerhamomyces anomalus
1033 Torulaspora delbruecki
1036 Torulaspora delbruecki
1147 Pichia kluyveri
1150 Pichia kluyveri
1151 Pichia kluyveri
1153 Pichia kluyveri
1148 Pichia kluyveri
1263 Cryptococcus victoriae
1268 Cryptococcus weringae
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pH 8.0 and 0.1 mM EDTA), 2 μLof RNase (10 mg/mL) 
and stored at ‑20°C until used.
2.4. PCR amplification
Primers ITS3 (5´–GCA TCG ATG AAG AAC GCA 
GC–3´) and ITS4 (5´–TCC TCC GCT TAT TGA TAT GC–3´) 
previously reported were used to amplify the ITS2‑5.8S 
rDNA from the isolates (White et al., 2003). Amplification 
was performed using 5-10 ng of fungal DNA as template 
in a 50μL mix containing 100 ng of each primer, 10 μM 
of deoxyribonucleotide triphosphate mixture, 2.5 mM of 
magnesium chloride, 5 μL of 10X PCR buffer (200 mM 
Tris, pH 8.4; and 500 mM KCl) and 2.5 U of TaqDNA 
polymerase (Invitrogen, Carlsbad, CA, USA). A reaction 
mix without a template was used as a negative control. 
Amplification consisted of an initial denaturation step 
of 5 minutes at 94°C, followed by 35 cycles. Each cycle 
consisted of a denaturation step at 95°C for 1 minute, 
annealing at 55°C for 1 minute and elongation at 72°C 
for 1.5 minutes, with a final elongation step at 72°C for 
5 minutes, in a PTC‑100 thermocycler (MJ Research, 
Waltham, MA, USA). All PCR products were separated 
by electrophoresis in 3.5% agarose electrophoresis gels 
stained with ethidium bromide and visualized with the 
software LabImage 1D version 3.4.0 (Kapelan Bio-Imaging, 
Leipzig, Germany). Afterwards, samples were stored at 
‑20°C until used.
2.5. Selection of restriction enzymes
The nucleotide sequences of the ITS2‑5.8S rDNA of 
various Candida species were analyzed first in silico using 
the NEBcutter software (New England BioLabs, Ipswich, 
MA, USA) to determine the different restriction patterns 
generated by the endonucleases. We selected RsaI, AlwI,, 
XmaI,, XhoI, and AatII due to the differential restriction 
patterns generated by them (Table 2).
2.6. Restriction fragment length polymorphisms
PCR‑amplified ITS2‑5.8S rDNA fragments from 
clinical isolates were digested with selected endonucleases 
in the appropriate buffer provided by the manufacturer 
(New England Biolabs, Ipswich, MA, USA). Digestion 
was carried out for 12 hours at 37°C, in a total volume of 
20 μL containing 10 μL of the PCR product, 5 U of each 
restriction enzyme and the respective buffer solution. 
Digested materials were separated by electrophoresis in 
8.0% polyacrylamide gel stained with ethidium bromide 
and the restriction fragments were analyzed using the 
LabImage 1D version 3.4.0 (Kapelan Bio-Imaging, 
Leipzig, Germany).
2.6. Killer assays
The screening of killer activity was performed as 
reported previously (Robledo-Leal et al., 2012), using 
YEPD‑MB agar (0.3% Yeast extract, 0.3% Malt extract, 
0.5% Peptone, 2% Glucose, 2% Agar and 0.003% Methylene 
blue, adjusted to pH 4.5 with 0.1 M citrate-phosphate 
buffer). Twenty‑four‑hour‑old cultures of the clinical isolates 
were mixed with the YEPD‑MB agar to obtain a final 
concentration of 1x106 cells per mL. After homogenization, 
media was poured onto Petri plates. Killer strains were 
streaked as thick smears over the sensitive lawn and 
replicates were made for incubation at 25°C for up to 72 h. 
The appearance of an inhibition zone surrounding the killer 
yeast bordered with a halo of dark-blue-stained cells was 
considered a positive indication of the presence of killer 
activity (Figure 1). Once the results were obtained, each 
assay was repeated for confirmation and reproducibility.
Table 2. Differential restriction patterns employed in this study.
Species
GenBank
accession 
number
ITS2,
5.8S and 28S 
partial sequence 
of rDNA (nt)
Restriction 
enzyme
Restriction 
fragments 
length (nt)
No. of clinical 
isolates 
identified
C. rugosa EU663569 271 RsaI 234, 37 0
C. albicans EU663565 335 AlwI 208, 127 23
C. tropicalis EU796734 327 XmaI 186, 141 13
C. lusitaniae EU663568 255 XhoI 159, 84, 12 0
C. guilliermondii EU663566 378 RsaI 210, 168 0
C. parapsilosis ATCC 22019 311 RsaI 228, 83 24
ITS: Internal Transcribed Spacer; nt: nucleotides.
Figure 1. Sample of a killer assay. Strains 1123 and 1144 in 
the plate (arrowheads) exhibit the killer phenotype.
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3. Results
Amplification of the ITS2‑5.8S rDNA region of the 
different reference Candida species generated PCR products 
ranging 271 to 378 base pairs (bp) in size (Figure 2). Enzymes 
that gave differential restriction fragment lengths in silico 
were employed in vitro to evaluate their differentiation 
of this strategy; electrophoresis in 8.0% polyacrylamide 
gel showed that the target bands corresponded to those 
predicted in silico.
To evaluate the reliability of the PCR/RFLP strategy 
used to identify clinical isolates of Candida, we extracted 
genomic DNA from 60 Candida isolates obtained from 
invasive infection cases. At least 100 ng of DNA were 
used for the ITS2‑5.8S rDNA amplification. Restriction 
resulted in 23 isolates identified as C. albicans using 
AlwI, 24 isolates as C. parapsilosis using RsaI, and 13 as 
C. tropicalis using XmaI.
3.1. Susceptibility to killer yeasts
All of the isolates were assayed against killer yeasts 
as described above (Table 3). Forty‑five isolates (75%) 
were sensitive against at least one killer yeast and the 
15 remaining isolates were not inhibited by any killer 
strain. Candida albicans was the most susceptible group, 
with 142 combinations resulting in inhibition, compared 
to 53 in C. parapsilosis and 27 in C. tropicalis. With the 
exception of CP21, C. parapsilosis had the narrowest range 
of susceptibility, with only 6 different strains being able to 
inhibit them, while for C. albicans and C. tropicalis as many 
as 12 different killer yeasts were able to inhibit them. Killer 
strains 1123, 1127 and 1144 were the most active, inhibiting 
the growth of 24 clinical isolates, including every one of 
C. albicans. None of the other killer yeasts was able to 
inhibit a whole species group. The most susceptible strains 
were also within the C. albicans group, being inhibited 
by 12 different killer strains. No species‑specific pattern 
of inhibition was obtained with this panel of killer yeasts.
4. Discussion
The incidence of pathogenic fungal species has a 
critical impact on clinical outcome in patients with invasive 
fungal infections, especially in immunocompromised 
patients. Although most of the clinically relevant fungal 
infections are caused by Candida species, it is important to 
identify the specific etiological agent to make an adequate 
choice of the antifungal therapy (Messer et al., 2009; 
Bourgeois et al., 2010). In order to provide a more rapid 
and reliable method for the identification of fungal species 
in invasive candidiasis, a number of molecular techniques 
have been developed. Several methods for specific fungal 
species identification are based on ITS2 ribosomal region 
variability, which is flanked by conserved sequences of rDNA 
(Fujita et al., 2001; Ferrer et al., 2001; Trost et al., 2004). 
The identification of fungal species using the ITS2 region 
has been described previously by Landlinger et al. (2009). 
They established a strategy based on PCR‑fragment length 
analysis of the ITS2 region to identify fungal species from 
clinical specimens. The PCR/RFLP technique differentiated 
seven clinically important species of Candida. A limitation 
of a single ITS2‑5.8S rDNA PCR fragment length analysis 
is the low variation of the fragment sizes between certain 
species, such as C. albicans and C. tropicalis, but they 
exhibit variation in their nucleotide sequences that are 
exploitable for differentiation using restriction enzymes. 
The site AlwI was conserved in 23 clinical isolates 
that had been previously identified by microbiological 
techniques as C. albicans, and the site XmaI was present 
in 13 isolates identified as C. tropicalis. Killer activity 
depends on various factors being temperature and pH some 
of the most relevant, but the nature of the sensitive yeast 
may be the most important. Our experiments exhibit the 
strain-related property of the killer phenomenon as described 
by Golubev (1998). While some killer toxins have a broad 
spectrum of activity, in theory there is no such thing as a 
“universal” killer yeast, for it depends on receptors and thus 
phylogenic relatedness. Yeasts may be resistant to certain 
killer toxins due to the lack of receptors, or immune due 
to either mutations or cross-protection resulting from the 
secretion of a similar toxin. Metschnikowia pulcherrima 
strains 1023, 1123 and 1144 showed a complete inhibition 
of the C. albicans group; while this species’ antimicrobial 
effect has been related to the production of pulcherrimic 
acid which is converted to the iron sequestering compound 
pulcherremin, instead of a proteinaceous agent, differences 
in the inhibition spectrum suggest the possibility of a killing 
factor different from or additional to this. On the other hand, 
strains 1153 (P. kluyveri) and 1025 (W. anomalus) exhibited 
a broad spectrum of inhibition as well (16 and 15 inhibitions 
respectively); both species have been reported before as 
producers of killer toxins and while these strains were 
Figure 2. PCR/RFLP of the ITS2‑5.8S region of the rRNA 
gene from different Candida species. (A) PCR‑amplified 
fragments of the mentioned region plus restriction enzyme 
used. Lanes: 1: C. albicans + AlwI (208 and 127 bp); 
2: C. tropicalis + XmaI (186 and 141 bp); 3: C. lusitaniae 
+ XhoI (84, 96 and 159 bp); 4: C. guilliermondii + RsaI 
(210 and 168 bp); 5: C. parapsilosis + RsaI (228 and 83 bp); 
6: C. rugosa + RsaI (37 and 234 bp). (B) Predicted (in silico) 
length and restriction map of the PCR‑amplified fragments 
of the ITS2‑5.8S region from different Candida species.
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Table 3. Interactions between killer yeasts and clinical isolates (only killer yeasts with positive reactions are shown).
Clinical
isolates
Killer yeasts
1250 1127 1144 1123 1023 1025 1027 1015 1018 1026 1147 1153 1268
CP01 +
CP02 +
CP03 + +
CP04
CP05
CP06 + +
CP07
CP08 + + + +
CP09 + + + +
CP10 + + +
CP11
CP12
CP13 +
CP14 + + +
CP15 +
CP16 + +
CP17 + + + +
CP18 + + + +
CP19 + + + +
CP20 + + +
CP21 + + + + + + +
CP22 + + + +
CP23 + + +
CP24
CA01 + + +
CA02 + + + + + + + + + + + +
CA03 + + + + + + + + + + + +
CA04 + + +
CA05 + + + + + + +
CA06 + + + + + + + + +
CA07 + + +
CA08 + + + +
CA09 + + + + +
CA10 + + + + + + + +
CA11 + + + + +
CA12 + + +
CA13 + + + +
CA14 + + + + + + + + + + + +
CA15 + + +
CA16 + + + + + + + +
CA17 + + + + + + +
CA18 + + +
CA19 + + + + + + + + +
CA20 + + +
CA21 + + +
CA22 + + + + + + + + +
CA23 + + + + + + +
CT01
CT02 + + + + + + + + +
+: positive inhibition; CP: Candida parapsilosis; CA: Candida albicans; CT: Candida tropicalis.
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not able to inhibit any Candida species group completely, 
they encourage the potential application of killer yeasts 
from the same species with a broader activity towards new 
antifungal therapies, both topical and systemic.
Killer activity is present in a wide diversity of yeasts but 
since the appropriate sensitive strain has to be used, many 
yeast species may have been misidentified as non‑killer. 
It has been possible to differentiate between species of 
pathogenic yeasts using the killer system (Coutinho and 
Paula 1998; Scheid et al. 2010; Boekhout and Scorzetti 
1997), and we suggest that it could be done for Candida 
species as well if a more taxonomically diverse panel 
of killer strains is employed. This would represent a 
rapid and low cost diagnostic tool. The value of such 
strategy would have a direct impact on therapy, due to 
the antifungal susceptibility differences among species 
(Treviño‑Rangel et al., 2012; Fothergill et al., 2014).
On the other hand, antifungal resistance is a widely-reported 
issue that has become increasingly important, which has 
promoted the search for non-synthetic alternative, including 
plant extracts (Höfling et al., 2010). Currently, there is a 
remarkable need for better antifungals with high specificity 
and reduced toxicity. In our results, 3 yeasts were able to 
kill every C. albicans strain, suggesting that their killer 
toxin could potentially be used as a therapeutic alternative 
via the production of “antibiododies” as described and 
demonstrated by Polonelli et al. (2011). While these yeasts 
were not able to kill every Candida strain in our study, the 
extraordinary diversity of yeasts makes it highly probable 
for the existence of strains with a wider range of action or 
a specific effect against other species of pathogenic fungi. 
Uncommon yeasts from non-conventional sites, such as 
those reported by Moraes et al. (2005) may prove useful 
in accomplishing this.
Follow-up experiments to investigate the inhibitory 
nature of M. pulcherrima strains and towards the search 
for a killer panel able to differentiate among Candida 
species, as well as new killer yeasts capable of inhibiting 
other pathogenic fungi, are ensured.
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